Clinical Decision Support Systems (CDSS) Market - Global Forecast to 2030
商品番号 : SMB-17946
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年5月 |
| ページ数 | 308 |
| 図表数 | 379 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
本レポートは、臨床意思決定支援システム市場を分析しています。コンポーネント、提供形態、製品、モデル、インタラクティブ性、用途、設定、タイプ、地域に基づき、様々な市場セグメントの市場規模と将来の成長ポテンシャルを推定することを目的としています。また、市場成長に影響を与える要因（推進要因、機会、課題など）も分析し、市場の利害関係者にとっての機会と課題を評価しています。さらに、ミクロ市場の成長傾向、見通し、そして臨床意思決定支援システム市場全体への貢献についても調査しています。さらに、5つの主要地域における市場セグメントの収益予測も提供しています。さらに、この市場における主要プレーヤーの競合分析、企業概要、製品ラインナップ、最近の動向、主要な市場戦略についても提供しています。
The global clinical decision support systems (CDSS) market is projected to reach USD 3.89 billion by 2030 from USD 2.25 billion in 2024, at a CAGR of 9.6% during the forecast period. The growth of this market is primarily driven by implementing government regulations and initiatives to promote the adoption of HIT solutions, increasing adoption of CDSS-enabled EHRs, growing collaborations and partnerships between stakeholders, rising incidence of medication errors, and the development of mHealth and big data tools. However, high investment requirements for the implementation of CDSS and inadequate interoperability, coupled with rising data security concerns, are factors expected to restrain the growth of this market during the forecast period.
世界の臨床意思決定支援システム（CDSS）市場は、2024年の22億5,000万米ドルから2030年には38億9,000万米ドルに達し、予測期間中に9.6%の年平均成長率（CAGR）で成長すると予測されています。この市場の成長は、主に、医療情報技術（HIT）ソリューションの導入を促進するための政府規制や取り組みの実施、CDSS対応の電子医療記録（EHR）の導入増加、関係者間の連携・パートナーシップの拡大、投薬ミスの増加、mHealthおよびビッグデータツールの開発によって牽引されています。しかしながら、CDSS導入のための高額な投資要件、不十分な相互運用性、そしてデータセキュリティへの懸念の高まりが、予測期間中の市場成長を抑制する要因となることが予想されます。
The software segment is expected to register the highest growth during the forecast period.
By component, the clinical decision support systems market is divided into services, software, and hardware. The software segment accounted for the fastest-growing segment of this market in 2024. It is driven primarily by the increasing adoption of integrated software solutions that seamlessly work with electronic health records (EHRs) and other clinical systems. These software platforms offer enhanced functionalities such as real-time alerts, data analytics, and personalized recommendations, which improve clinical efficiency and decision-making. Advancements in AI and machine learning are further driving innovation in CDSS software, enabling more intelligent, scalable, and user-friendly applications. The shift toward cloud-based deployments and subscription-based models is making these solutions more accessible and cost-effective for healthcare providers, further fueling growth in this segment.
The on-premise CDSS segment registered the largest share of the clinical decision support systems market in 2024.
By delivery mode, the clinical decision support systems market is divided into on-premise and cloud-based modes. In 2024, the on-premise CDSS segment is projected to hold the largest share of the clinical decision support systems market, primarily due to heightened concerns around data security and control, especially among large hospitals and healthcare institutions. On-premise solutions allow organizations to manage sensitive patient data within their infrastructure, reducing the risk of breaches and ensuring compliance with strict data protection regulations. These systems also offer greater customization, seamless integration with existing IT infrastructure, and flexibility in managing software upgrades, allowing institutions to test new features and train staff without disrupting clinical operations.
North America dominated the clinical decision support systems market in 2024.
North America accounted for the largest share of the global clinical decision support systems market in 2024. The existence of major industry participants, regulatory directives that support CDSS adoption, and the rise in medication errors in the US and Canada contribute to these trends. Forecasts indicate that the Asia Pacific region will witness the highest CAGR throughout the projected timeframe. This is due to factors such as the escalating prevalence of chronic illnesses and the growing attention of diverse market stakeholders toward emerging Asian nations. These factors are anticipated to propel the expansion of the clinical decision support systems market in the Asia Pacific region.
The breakdown of primary participants is as mentioned below:
- By Company Type – Tier 1: 45%, Tier 2: 35%, and Tier 3: 20%
- By Designation – Directors: 26%, Manager: 17%, and Others: 57%
- By Region – North America: 40%, Europe: 20%, Asia Pacific: 30%, Latin America: 6%, and Middle East & Africa: 4%
List of Companies Profiled in the Report
o Wolters Kluwer N.V. (Netherlands)
o Oracle (US)
o Merative (US)
o Change Healthcare (US)
o Veradigm Inc. (US)
o athenahealth (US)
o Epic Systems Corporation (US)
o Elsevier B.V. (Netherlands)
o Zynx Health (US)
o Koninklijke Philips N.V. (Netherlands)
o Medical Information Technology, Inc. (US)
o NextGen Healthcare, Inc. (US)
o CureMD Healthcare (US)
o Siemens Healthineers (Germany)
o EBSCO Information Services (US)
o GE HealthCare (US)
o eClinicalWorks (US)
o The Medical Algorithms Company (UK)
o RAMPmedical (Germany)
o Hera-MI (France)
o CareCloud, Inc. (US)
o VisualDx (US)
o Premier, Inc. (US)
o First Databank, Inc. (US)
o Strata Decision Technology (US).
Research Coverage
The report analyzes the clinical decision support systems market. It aims to estimate the market size and future growth potential of various market segments, based on component, delivery mode, product, model, interactivity level, application, setting, type, and region. The report also analyses factors (such as drivers, opportunities, and challenges) affecting market growth. It evaluates the opportunities and challenges for market stakeholders. The report also studies micro markets with respect to their growth trends, prospects, and contributions to the total clinical decision support systems market. The report forecasts the revenue of the market segments with respect to five major regions. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report
This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a higher share of the market. Firms purchasing the report could use one or a combination of the strategies mentioned below to strengthen their positions in the market.
This report provides insights on:
Analysis of key drivers (implementation of government regulations & initiatives to promote adoption of HCIT solutions, increasing adoption of CDSS-enabled EHRs, growing collaborations & partnerships between stakeholders, growing incidence of medication errors, development of big data and mHealth tools), restraints (data security concerns related to cloud-based CDSS, inadequate interoperability), opportunities (growth potential of emerging markets, social media integration and rising technological advancements), challenges (requirement of high investments for implementation of CDSS infrastructure, shortage of skilled IT professionals in healthcare industry)
- Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new software launches in the clinical decision support systems market
- Market Development: Comprehensive information on the lucrative emerging markets, type of component, product, type, model, delivery mode, application, interactivity level, setting, and region
- Market Diversification: Exhaustive information about the software portfolios, growing geographies, recent developments, and investments in the clinical decision support systems market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global clinical decision support systems market, such as Wolters Kluwer N.V. (Netherlands), Oracle (US), Merative (US), Change Healthcare (US), Veradigm Inc. (US), athenahealth (US), Epic Systems Corporation (US), Elsevier B.V. (Netherlands), Zynx Health (US), and Koninklijke Philips N.V. (Netherlands)
Table of Contents
1 INTRODUCTION 30
1.1 STUDY OBJECTIVES 30
1.2 MARKET DEFINITION 30
1.3 MARKET SCOPE 31
1.3.1 MARKETS SEGMENTATION AND REGIONS COVERED 31
1.3.2 INCLUSIONS AND EXCLUSIONS 32
1.3.3 YEARS CONSIDERED 33
1.4 CURRENCY CONSIDERED 33
1.5 STAKEHOLDERS 33
1.6 SUMMARY OF CHANGES 34
2 RESEARCH METHODOLOGY 35
2.1 RESEARCH DATA 35
2.1.1 SECONDARY DATA 36
2.1.1.1 Key data from secondary sources 37
2.1.2 PRIMARY RESEARCH 37
2.1.2.1 Key data from primary sources 39
2.1.2.2 Key industry insights 39
2.2 MARKET SIZE ESTIMATION 40
2.2.1 APPROACH 1: REVENUE SHARE ANALYSIS 42
2.2.2 APPROACH 2: DEMAND-SIDE ANALYSIS 42
2.2.3 APPROACH 3: BOTTOM-UP AND SEGMENTAL EXTRAPOLATION 43
2.3 GROWTH FORECAST MODEL 44
2.3.1 PRIMARY INTERVIEWS 46
2.3.2 TOP-DOWN APPROACH 46
2.3.3 SEGMENT ASSESSMENT 46
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 47
2.5 RESEARCH ASSUMPTIONS 48
2.6 RESEARCH LIMITATIONS 48
2.6.1 SCOPE-RELATED LIMITATIONS 48
2.6.2 METHODOLOGY-RELATED LIMITATIONS 48
2.7 RISK ASSESSMENT 49
3 EXECUTIVE SUMMARY 50
4 PREMIUM INSIGHTS 57
4.1 CLINICAL DECISION SUPPORT SYSTEMS MARKET OVERVIEW 57
4.2 NORTH AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY PRODUCT AND COUNTRY 58
4.3 CLINICAL DECISION SUPPORT SYSTEMS MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES 58
4.4 CLINICAL DECISION SUPPORT SYSTEMS MARKET: REGIONAL MIX 59
4.5 CLINICAL DECISION SUPPORT SYSTEMS MARKET: DEVELOPED VS. DEVELOPING MARKETS 59
5 MARKET OVERVIEW 60
5.1 INTRODUCTION 60
5.2 MARKET DYNAMICS 60
5.2.1 DRIVERS 61
5.2.1.1 Increasing government regulations for HCIT implementation 61
5.2.1.2 Growing adoption of CDSS-enabled electronic health records 62
5.2.1.3 Rising incidence of medication errors 63
5.2.2 RESTRAINTS 63
5.2.2.1 Data security concerns 63
5.2.2.2 Inadequate interoperability for patient management solutions 64
5.2.3 OPPORTUNITIES 64
5.2.3.1 Development of big data and mHealth tools 64
5.2.3.2 High growth potential in emerging economies 65
5.2.3.3 Rising technological advancements 65
5.2.4 CHALLENGES 66
5.2.4.1 High capital investments for CDSS infrastructure 66
5.2.4.2 Shortage of skilled IT professionals 66
5.3 INDUSTRY TRENDS 67
5.3.1 GROWING APPLICATIONS OF AI 67
5.3.2 INCREASING FOCUS ON MOBILE AND CLOUD-BASED SOLUTIONS 67
5.3.3 ADOPTION OF HCIT SOLUTIONS 68
5.3.4 GRADUAL SHIFT OF ACCOUNTABILITY FROM PAYERS TO PROVIDERS 68
5.3.5 INCREASING DEMAND FOR VALUE-BASED HEALTHCARE 69
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 70
5.5 PRICING ANALYSIS 70
5.5.1 AVERAGE SELLING PRICE OF KEY PLAYER, BY PRODUCT 70
5.5.2 AVERAGE SELLING PRICE TREND, BY REGION 71
5.6 VALUE CHAIN ANALYSIS 72
5.7 ECOSYSTEM ANALYSIS 73
5.8 TECHNOLOGY ANALYSIS 74
5.9 PATENT ANALYSIS 75
5.9.1 PATENT PUBLICATION TRENDS FOR CLINICAL DECISION SUPPORT SYSTEMS 75
5.9.2 JURISDICTION ANALYSIS 76
5.10 TRADE ANALYSIS 79
5.10.1 IMPORT DATA FOR HS CODE 901890 79
5.10.2 EXPORT DATA FOR HS CODE 901890 80
5.11 KEY CONFERENCES AND EVENTS, 2025–2026 81
5.12 CASE STUDY ANALYSIS 82
5.12.1 USE OF EVIDENCE-BASED NURSING KNOWLEDGE FOR PATIENT CARE 82
5.12.2 USE OF KNOWLEDGE ANALYZER FOR WORKFLOW IMPROVEMENTS 82
5.12.3 IMPROVED RESPONSE TIME AND PHYSICIAN EFFICIENCY IN HEALTHCARE FACILITIES WITH ELECTRONIC HEALTH RECORD 83
5.12.4 ENHANCED EFFICIENCY AND VALUE-BASED CARE WITH AI-POWERED CDSS 83
5.13 TARIFF AND REGULATORY LANDSCAPE 84
5.13.1 TARIFF FOR CDSS HARDWARE 84
5.13.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 84
5.13.3 REGULATORY ANALYSIS 88
5.13.3.1 North America 88
5.13.3.1.1 Federal Food, Drug, and Cosmetic Act (FD&C Act) 88
5.13.3.1.2 Health Insurance Portability and Accountability Act (HIPAA) 89
5.13.3.1.3 Affordable Care Act, 2010 89
5.13.3.1.4 Health Information Technology for Economic and Clinical Health Act, 2009 (HITECH) 89
5.13.3.1.5 Consumer Privacy Protection Act, 2017 90
5.13.3.2 Europe 90
5.13.3.2.1 General Data Protection Regulation (GDPR) 90
5.13.3.2.2 EU Cybersecurity Act 90
5.13.3.3 Asia Pacific 90
5.13.3.3.1 China’s Cyber Security Law (CSL) 90
5.13.3.4 Middle East & Africa 90
5.13.3.4.1 Protection of Personal Information Act, South Africa 90
5.13.3.4.2 Cloud Computing Regulatory Framework, South Africa 90
5.13.3.4.3 Federal Law No. (2) of 2019, UAE 91
5.13.3.5 Latin America 91
5.13.3.5.1 Lei Geral de Proteção de Dados (General Data Protection Law), Brazil 91
5.14 PORTER’S FIVE FORCES ANALYSIS 91
5.14.1 BARGAINING POWER OF SUPPLIERS 92
5.14.2 BARGAINING POWER OF BUYERS 92
5.14.3 THREAT OF NEW ENTRANTS 92
5.14.4 THREAT OF SUBSTITUTES 93
5.14.5 INTENSITY OF COMPETITIVE RIVALRY 93
5.15 BUSINESS MODELS 93
5.16 KEY STAKEHOLDERS AND BUYING CRITERIA 95
5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS 95
5.16.2 BUYING CRITERIA 96
5.17 IMPACT OF 2025 US TARIFF 96
5.17.1 INTRODUCTION 96
5.17.2 KEY TARIFF RATES 97
5.17.3 PRICE IMPACT ANALYSIS 98
5.17.4 IMPACT ON COUNTRY/REGION 98
5.17.4.1 US 98
5.17.4.2 Europe 99
5.17.4.3 Asia Pacific 99
5.17.5 IMPACT ON END-USE INDUSTRIES 100
5.17.5.1 Inpatient settings 100
5.17.5.2 Ambulatory care settings 100
5.17.6 CONCLUSION 101
6 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT 102
6.1 INTRODUCTION 103
6.2 SERVICES 103
6.2.1 INCREASING RELIANCE OF HEALTHCARE IT INDUSTRY ON SERVICES TO DRIVE MARKET 103
6.3 SOFTWARE 105
6.3.1 FREQUENT NEED FOR UPGRADES AND IMPROVEMENTS IN SOFTWARE APPLICATIONS TO PROPEL MARKET 105
6.4 HARDWARE 106
6.4.1 NEED TO OPTIMIZE SOFTWARE TO AUGMENT GROWTH 106
7 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY PRODUCT 107
7.1 INTRODUCTION 108
7.2 INTEGRATED CDSS 108
7.2.1 GROWING FOCUS ON QUALITY HEALTHCARE AND REDUCING MEDICATION ERRORS TO BOOST MARKET 108
7.3 STANDALONE CDSS 110
7.3.1 LACK OF REPORTING AND ELECTRONIC HEALTH RECORDS TO LIMIT GROWTH 110
8 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE 111
8.1 INTRODUCTION 112
8.2 THERAPEUTIC CDSS 112
8.2.1 SEAMLESS INTEGRATION INTO CLINICAL WORKFLOWS TO PROMOTE GROWTH 112
8.3 DIAGNOSTIC CDSS 113
8.3.1 RISING USE OF ALGORITHMS FOR EFFECTIVE REAL-TIME DIAGNOSIS TO SUPPORT GROWTH 113
9 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY MODEL 115
9.1 INTRODUCTION 116
9.2 KNOWLEDGE-BASED CDSS 116
9.2.1 INCREASING FOCUS ON PRECISION COURSE OF TREATMENT TO AID GROWTH 116
9.3 NON-KNOWLEDGE-BASED CDSS 118
9.3.1 GROWING ADOPTION OF ARTIFICIAL INTELLIGENCE TO DRIVE MARKET 118
10 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DELIVERY MODE 120
10.1 INTRODUCTION 121
10.2 ON-PREMISE CDSS 121
10.2.1 LOWER RISK OF DATA BREACH AND ABILITY TO CHOOSE MULTIPLE VENDORS TO SUSTAIN GROWTH 121
10.3 CLOUD-BASED CDSS 122
10.3.1 FLEXIBLE AND SCALABLE FEATURES TO CONTRIBUTE TO GROWTH 122
11 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY APPLICATION 124
11.1 INTRODUCTION 125
11.2 CONVENTIONAL CDSS 125
11.2.1 ABILITY TO PROVIDE DIAGNOSTIC ASSISTANCE AND PRESCRIPTION DECISION SUPPORT TO DRIVE MARKET 125
11.3 ADVANCED CDSS 126
11.3.1 REAL-TIME EVIDENCE AND PROTOCOL VALIDATION BENEFITS TO STIMULATE GROWTH 126
12 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INTERACTIVITY LEVEL 128
12.1 INTRODUCTION 129
12.2 ACTIVE CDSS 129
12.2.1 ABILITY TO ENABLE OPTIMAL DECISION-MAKING WITH MINIMAL ERRORS TO ACCELERATE GROWTH 129
12.3 PASSIVE CDSS 130
12.3.1 MINIMAL DISRUPTION TO WORKFLOWS TO ENCOURAGE GROWTH 130
13 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY SETTING 132
13.1 INTRODUCTION 133
13.2 INPATIENT SETTINGS 133
13.2.1 GROWING FOCUS ON IMPROVING HEALTHCARE OPERATIONS IN HOSPITALS TO PROPEL MARKET 133
13.3 AMBULATORY CARE SETTINGS 134
13.3.1 RISING NEED TO CURB HEALTHCARE COSTS TO FACILITATE GROWTH 134
14 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY REGION 136
14.1 INTRODUCTION 137
14.2 NORTH AMERICA 138
14.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 139
14.2.2 US 142
14.2.2.1 Growing focus on value-based care to drive market 142
14.2.3 CANADA 145
14.2.3.1 Increasing regulations regarding safety & quality care to speed up growth 145
14.3 EUROPE 148
14.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 148
14.3.2 GERMANY 152
14.3.2.1 Favorable government support for adoption of electronic medical records to propel market 152
14.3.3 UK 155
14.3.3.1 Rising establishment of healthcare facilities to accelerate growth 155
14.3.4 FRANCE 158
14.3.4.1 Growing focus on improving healthcare coordination to drive market 158
14.3.5 ITALY 161
14.3.5.1 Rising need for evidence-based CDSS to drive market 161
14.3.6 SPAIN 164
14.3.6.1 Growing focus on improving patient outcomes to boost market 164
14.3.7 REST OF EUROPE 167
14.4 ASIA PACIFIC 170
14.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 171
14.4.2 JAPAN 175
14.4.2.1 Rising need to digitize patient records to bolster growth 175
14.4.3 CHINA 178
14.4.3.1 Favorable government support to drive market 178
14.4.4 INDIA 181
14.4.4.1 Rising adoption of telemedicine to favor growth 181
14.4.5 REST OF ASIA PACIFIC 184
14.5 LATIN AMERICA 187
14.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 187
14.5.2 BRAZIL 191
14.5.2.1 Rising demand to digitize patient records to amplify growth 191
14.5.3 MEXICO 194
14.5.3.1 Established healthcare reforms to contribute to growth 194
14.5.4 REST OF LATIN AMERICA 197
14.6 MIDDLE EAST & AFRICA 200
14.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 200
14.6.2 GCC COUNTRIES 203
14.6.2.1 Growing investments in healthcare infrastructure to propel market 203
14.6.3 REST OF MIDDLE EAST & AFRICA 206
15 COMPETITIVE LANDSCAPE 209
15.1 INTRODUCTION 209
15.2 KEY PLAYER STRATEGIES, 2022–2025 209
15.3 REVENUE ANALYSIS, 2020–2024 211
15.4 MARKET SHARE ANALYSIS, 2024 212
15.5 COMPANY VALUATION AND FINANCIAL METRICS 213
15.6 BRAND/PRODUCT COMPARATIVE ANALYSIS 215
15.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 216
15.7.1 STARS 216
15.7.2 EMERGING LEADERS 216
15.7.3 PERVASIVE PLAYERS 216
15.7.4 PARTICIPANTS 216
15.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 218
15.7.5.1 Company footprint 218
15.7.5.2 Region footprint 218
15.7.5.3 Application & product footprint 219
15.7.5.4 Type footprint 219
15.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 220
15.8.1 PROGRESSIVE COMPANIES 220
15.8.2 RESPONSIVE COMPANIES 220
15.8.3 DYNAMIC COMPANIES 220
15.8.4 STARTING BLOCKS 220
15.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 222
15.8.5.1 Detailed list of key startups/SMEs 222
15.8.5.2 Competitive benchmarking of key startups/SMEs 223
15.9 COMPETITIVE SCENARIO 223
15.9.1 SOLUTION LAUNCHES/ENHANCEMENTS/APPROVALS 223
15.9.2 DEALS 225
15.9.3 OTHER DEVELOPMENTS 227
16 COMPANY PROFILES 228
16.1 KEY PLAYERS 228
16.1.1 EPIC SYSTEMS CORPORATION 228
16.1.1.1 Business overview 228
16.1.1.2 Solutions offered 228
16.1.1.3 Recent developments 229
16.1.1.3.1 Solution launches/enhancements/approvals 229
16.1.1.3.2 Deals 229
16.1.1.3.3 Other developments 230
16.1.1.4 MnM view 230
16.1.1.4.1 Key strengths 230
16.1.1.4.2 Strategic choices 230
16.1.1.4.3 Weaknesses and competitive threats 231
16.1.2 WOLTERS KLUWER N.V. 232
16.1.2.1 Business overview 232
16.1.2.2 Solutions offered 233
16.1.2.3 Recent developments 234
16.1.2.3.1 Solution launches/enhancements/approvals 234
16.1.2.3.2 Deals 235
16.1.2.3.3 Other developments 237
16.1.2.4 MnM view 237
16.1.2.4.1 Key strengths 237
16.1.2.4.2 Strategic choices 237
16.1.2.4.3 Weaknesses and competitive threats 237
16.1.3 ORACLE 238
16.1.3.1 Business overview 238
16.1.3.2 Solutions offered 239
16.1.3.3 Recent developments 240
16.1.3.3.1 Solution launches/enhancements/approvals 240
16.1.3.3.2 Deals 240
16.1.3.4 MnM view 242
16.1.3.4.1 Key strengths 242
16.1.3.4.2 Strategic choices 242
16.1.3.4.3 Weaknesses and competitive threats 242
16.1.4 MERATIVE 243
16.1.4.1 Business overview 243
16.1.4.2 Solutions offered 243
16.1.4.3 Recent developments 244
16.1.4.3.1 Solution launches/enhancements/approvals 244
16.1.4.3.2 Deals 244
16.1.4.3.3 Other developments 244
16.1.4.4 MnM view 245
16.1.4.4.1 Key strengths 245
16.1.4.4.2 Strategic choices 245
16.1.4.4.3 Weaknesses and competitive threats 245
16.1.5 VERADIGM LLC 246
16.1.5.1 Business overview 246
16.1.5.2 Solutions offered 247
16.1.5.3 Recent developments 248
16.1.5.3.1 Solution launches/enhancements/approvals 248
16.1.5.3.2 Deals 249
16.1.5.3.3 Other developments 250
16.1.5.4 MnM view 250
16.1.5.4.1 Key strengths 250
16.1.5.4.2 Strategic choices 250
16.1.5.4.3 Weaknesses and competitive threats 251
16.1.6 OPTUM, INC. (UNITEDHEALTH GROUP) 252
16.1.6.1 Business overview 252
16.1.6.2 Solutions offered 253
16.1.6.3 Recent developments 253
16.1.6.3.1 Solution launches/enhancements/approvals 253
16.1.6.3.2 Deals 253
16.1.7 ATHENAHEALTH 254
16.1.7.1 Business overview 254
16.1.7.2 Solutions offered 254
16.1.7.3 Recent developments 255
16.1.7.3.1 Solution launches/enhancements/approvals 255
16.1.7.3.2 Deals 255
16.1.8 ELSEVIER (DIVISION OF RELX GROUP) 257
16.1.8.1 Business overview 257
16.1.8.2 Solutions offered 257
16.1.8.3 Recent developments 258
16.1.8.3.1 Solution launches/enhancements/approvals 258
16.1.8.3.2 Deals 259
16.1.9 ZYNX HEALTH, INC. 260
16.1.9.1 Business overview 260
16.1.9.2 Solutions offered 260
16.1.9.3 Recent developments 261
16.1.9.3.1 Solution launches/enhancements/approvals 261
16.1.9.3.2 Deals 262
16.1.9.3.3 Other developments 262
16.1.10 KONINKLIJKE PHILIPS N.V. 263
16.1.10.1 Business overview 263
16.1.10.2 Solutions offered 264
16.1.10.3 Recent developments 265
16.1.10.3.1 Product launches/enhancements/approvals 265
16.1.11 MEDICAL INFORMATION TECHNOLOGY, INC. 266
16.1.11.1 Business overview 266
16.1.11.2 Solutions offered 266
16.1.11.3 Recent developments 267
16.1.11.3.1 Product launches/enhancements/approvals 267
16.1.11.3.2 Deals 267
16.1.11.3.3 Other developments 269
16.1.12 NEXTGEN HEALTHCARE, INC. 270
16.1.12.1 Business overview 270
16.1.12.2 Solutions offered 271
16.1.12.3 Recent developments 272
16.1.12.3.1 Solution launches/enhancements/approvals 272
16.1.12.3.2 Deals 272
16.1.12.3.3 Other developments 273
16.1.13 CUREMD HEALTHCARE 274
16.1.13.1 Business overview 274
16.1.13.2 Solutions offered 274
16.1.13.2.1 Deals 276
16.1.13.2.2 Other developments 276
16.1.14 SIEMENS HEALTHINEERS AG 277
16.1.14.1 Business overview 277
16.1.14.2 Solutions offered 278
16.1.14.3 Recent developments 279
16.1.14.3.1 Deals 279
16.1.15 EBSCO INFORMATION SERVICES 280
16.1.15.1 Business overview 280
16.1.15.2 Solutions offered 280
16.1.15.3 Recent developments 282
16.1.15.3.1 Solution launches/enhancements/approvals 282
16.1.15.3.2 Deals 282
16.1.15.3.3 Other developments 283
16.1.16 GE HEALTHCARE 284
16.1.16.1 Business overview 284
16.1.16.2 Solutions offered 285
16.1.16.3 Recent developments 286
16.1.16.3.1 Solution launches/enhancements/approvals 286
16.1.16.3.2 Deals 286
16.1.16.3.3 Other developments 287
16.1.17 ECLINICALWORKS 288
16.1.17.1 Business overview 288
16.1.17.2 Solutions offered 288
16.1.17.3 Recent developments 289
16.1.17.3.1 Solution launches/enhancements/approvals 289
16.1.17.4 Recent developments 289
16.1.17.4.1 Deals 289
16.1.18 THE MEDICAL ALGORITHMS COMPANY LIMITED 291
16.1.18.1 Business overview 291
16.1.18.2 Solutions offered 291
16.1.19 CARECLOUD, INC. 292
16.1.19.1 Business overview 292
16.1.19.2 Solutions offered 293
16.1.19.3 Recent developments 294
16.1.19.3.1 Solution launches/enhancements/approvals 294
16.1.19.3.2 Deals 294
16.1.19.3.3 Expansions 295
16.1.20 RAMPMEDICAL 296
16.1.20.1 Business overview 296
16.1.20.2 Solutions offered 296
16.2 OTHER PLAYERS 297
16.2.1 MACUSOFT 297
16.2.2 HERA-MI 298
16.2.3 COHESIC INC. 298
16.2.4 MEDEA MIND 299
16.2.5 GLASS HEALTH 299
16.2.6 MEDECIPHER 300
17 APPENDIX 301
17.1 DISCUSSION GUIDE 301
17.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 304
17.3 CUSTOMIZATION OPTIONS 306
17.4 RELATED REPORTS 306
17.5 AUTHOR DETAILS 307
LIST OF TABLES
TABLE 1 CLINICAL DECISION SUPPORT SYSTEMS MARKET: INCLUSIONS AND EXCLUSIONS 32
TABLE 2 RISK ASSESSMENT ANALYSIS 49
TABLE 3 CLINICAL DECISION SUPPORT SYSTEMS MARKET: IMPACT ANALYSIS
OF MARKET DYNAMICS 61
TABLE 4 AVERAGE SELLING PRICE, BY REGION, 2024 (USD) 71
TABLE 5 CLINICAL DECISION SUPPORT SYSTEMS MARKET: ROLE OF COMPANIES
IN ECOSYSTEM 74
TABLE 6 TECHNOLOGICAL DEVELOPMENTS BY LEADING VENDORS 74
TABLE 7 INNOVATIONS AND PATENT REGISTRATIONS, 2019–2023 78
TABLE 8 IMPORT DATA FOR HS CODE 901890, BY COUNTRY,
2021–2024 (USD THOUSAND) 79
TABLE 9 EXPORT DATA FOR HS CODE 901890, BY COUNTRY,
2021–2024 (USD THOUSAND) 80
TABLE 10 CLINICAL DECISION SUPPORT SYSTEMS MARKET: KEY CONFERENCES AND EVENTS, 2025–2026 81
TABLE 11 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 84
TABLE 12 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86
TABLE 13 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87
TABLE 14 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88
TABLE 15 CLINICAL DECISION SUPPORT SYSTEMS MARKET: PORTER’S FIVE FORCES ANALYSIS 92
TABLE 16 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE (%) 95
TABLE 17 KEY BUYING CRITERIA FOR TOP THREE COMPONENTS 96
TABLE 18 US ADJUSTED RECIPROCAL TARIFF RATES 97
TABLE 19 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT,
2023–2030 (USD MILLION) 103
TABLE 20 CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 104
TABLE 21 CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION) 105
TABLE 22 CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR HARDWARE, BY COUNTRY, 2023–2030 (USD MILLION) 106
TABLE 23 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 108
TABLE 24 INTEGRATED CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 109
TABLE 25 STANDALONE CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 110
TABLE 26 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE,
2023–2030 (USD MILLION) 112
TABLE 27 THERAPEUTIC CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 113
TABLE 28 DIAGNOSTIC CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 114
TABLE 29 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY MODEL,
2023–2030 (USD MILLION) 116
TABLE 30 KNOWLEDGE-BASED CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 117
TABLE 31 NON-KNOWLEDGE-BASED CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 119
TABLE 32 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DELIVERY MODE,
2023–2030 (USD MILLION) 121
TABLE 33 ON-PREMISE CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 122
TABLE 34 CLOUD-BASED CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 123
TABLE 35 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 125
TABLE 36 CONVENTIONAL CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 126
TABLE 37 ADVANCED CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 127
TABLE 38 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INTERACTIVITY LEVEL,
2023–2030 (USD MILLION) 129
TABLE 39 ACTIVE CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 130
TABLE 40 PASSIVE CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 131
TABLE 41 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY SETTING,
2023–2030 (USD MILLION) 133
TABLE 42 CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR INPATIENT SETTINGS,
BY COUNTRY, 2023–2030 (USD MILLION) 134
TABLE 43 CLINICAL DECISION SUPPORT SYSTEMS MARKET FOR AMBULATORY CARE SETTINGS, BY COUNTRY, 2023–2030 (USD MILLION) 135
TABLE 44 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY REGION,
2023–2030 (USD MILLION) 137
TABLE 45 NORTH AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 139
TABLE 46 NORTH AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY COMPONENT, 2023–2030 (USD MILLION) 139
TABLE 47 NORTH AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY DELIVERY MODE, 2023–2030 (USD MILLION) 140
TABLE 48 NORTH AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 140
TABLE 49 NORTH AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE, 2023–2030 (USD MILLION) 140
TABLE 50 NORTH AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY MODEL, 2023–2030 (USD MILLION) 141
TABLE 51 NORTH AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY INTERACTIVITY LEVEL, 2023–2030 (USD MILLION) 141
TABLE 52 NORTH AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 141
TABLE 53 NORTH AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY SETTING, 2023–2030 (USD MILLION) 142
TABLE 54 US: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT,
2023–2030 (USD MILLION) 143
TABLE 55 US: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DELIVERY MODE,
2023–2030 (USD MILLION) 143
TABLE 56 US: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 143
TABLE 57 US: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE,
2023–2030 (USD MILLION) 144
TABLE 58 US: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY MODEL,
2023–2030 (USD MILLION) 144
TABLE 59 US: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INTERACTIVITY LEVEL, 2023–2030 (USD MILLION) 144
TABLE 60 US: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 145
TABLE 61 US: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY SETTING,
2023–2030 (USD MILLION) 145
TABLE 62 CANADA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT, 2023–2030 (USD MILLION) 146
TABLE 63 CANADA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DELIVERY MODE, 2023–2030 (USD MILLION) 146
TABLE 64 CANADA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 146
TABLE 65 CANADA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE,
2023–2030 (USD MILLION) 147
TABLE 66 CANADA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY MODEL,
2023–2030 (USD MILLION) 147
TABLE 67 CANADA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY INTERACTIVITY LEVEL, 2023–2030 (USD MILLION) 147
TABLE 68 CANADA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 148
TABLE 69 CANADA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY SETTING,
2023–2030 (USD MILLION) 148
TABLE 70 EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 149
TABLE 71 EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT, 2023–2030 (USD MILLION) 149
TABLE 72 EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DELIVERY MODE, 2023–2030 (USD MILLION) 150
TABLE 73 EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 150
TABLE 74 EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE,
2023–2030 (USD MILLION) 150
TABLE 75 EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY MODEL,
2023–2030 (USD MILLION) 151
TABLE 76 EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY INTERACTIVITY LEVEL, 2023–2030 (USD MILLION) 151
TABLE 77 EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 151
TABLE 78 EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY SETTING,
2023–2030 (USD MILLION) 152
TABLE 79 GERMANY: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT, 2023–2030 (USD MILLION) 153
TABLE 80 GERMANY: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DELIVERY MODE, 2023–2030 (USD MILLION) 153
TABLE 81 GERMANY: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 153
TABLE 82 GERMANY: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE,
2023–2030 (USD MILLION) 154
TABLE 83 GERMANY: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY MODEL,
2023–2030 (USD MILLION) 154
TABLE 84 GERMANY: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY INTERACTIVITY LEVEL, 2023–2030 (USD MILLION) 154
TABLE 85 GERMANY: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 155
TABLE 86 GERMANY: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY SETTING,
2023–2030 (USD MILLION) 155
TABLE 87 UK: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT,
2023–2030 (USD MILLION) 156
TABLE 88 UK: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DELIVERY MODE,
2023–2030 (USD MILLION) 156
TABLE 89 UK: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 156
TABLE 90 UK: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE,
2023–2030 (USD MILLION) 157
TABLE 91 UK: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY MODEL,
2023–2030 (USD MILLION) 157
TABLE 92 UK: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INTERACTIVITY LEVEL, 2023–2030 (USD MILLION) 157
TABLE 93 UK: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 158
TABLE 94 UK: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY SETTING,
2023–2030 (USD MILLION) 158
TABLE 95 FRANCE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT, 2023–2030 (USD MILLION) 159
TABLE 96 FRANCE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DELIVERY MODE, 2023–2030 (USD MILLION) 159
TABLE 97 FRANCE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 159
TABLE 98 FRANCE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE,
2023–2030 (USD MILLION) 160
TABLE 99 FRANCE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY MODEL,
2023–2030 (USD MILLION) 160
TABLE 100 FRANCE: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY INTERACTIVITY LEVEL, 2023–2030 (USD MILLION) 160
TABLE 101 FRANCE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 161
TABLE 102 FRANCE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY SETTING,
2023–2030 (USD MILLION) 161
TABLE 103 ITALY: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT,
2023–2030 (USD MILLION) 162
TABLE 104 ITALY: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DELIVERY MODE, 2023–2030 (USD MILLION) 162
TABLE 105 ITALY: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 162
TABLE 106 ITALY: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE,
2023–2030 (USD MILLION) 163
TABLE 107 ITALY: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY MODEL,
2023–2030 (USD MILLION) 163
TABLE 108 ITALY: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INTERACTIVITY LEVEL, 2023–2030 (USD MILLION) 163
TABLE 109 ITALY: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 164
TABLE 110 ITALY: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY SETTING,
2023–2030 (USD MILLION) 164
TABLE 111 SPAIN: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT,
2023–2030 (USD MILLION) 165
TABLE 112 SPAIN: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DELIVERY MODE, 2023–2030 (USD MILLION) 165
TABLE 113 SPAIN: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 165
TABLE 114 SPAIN: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE,
2023–2030 (USD MILLION) 166
TABLE 115 SPAIN: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY MODEL,
2023–2030 (USD MILLION) 166
TABLE 116 SPAIN: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INTERACTIVITY LEVEL, 2023–2030 (USD MILLION) 166
TABLE 117 SPAIN: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 167
TABLE 118 SPAIN: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY SETTING,
2023–2030 (USD MILLION) 167
TABLE 119 REST OF EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY COMPONENT, 2023–2030 (USD MILLION) 168
TABLE 120 REST OF EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY DELIVERY MODE, 2023–2030 (USD MILLION) 168
TABLE 121 REST OF EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 168
TABLE 122 REST OF EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE, 2023–2030 (USD MILLION) 169
TABLE 123 REST OF EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY MODEL, 2023–2030 (USD MILLION) 169
TABLE 124 REST OF EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY INTERACTIVITY LEVEL, 2023–2030 (USD MILLION) 169
TABLE 125 REST OF EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 170
TABLE 126 REST OF EUROPE: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY SETTING, 2023–2030 (USD MILLION) 170
TABLE 127 ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 172
TABLE 128 ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT, 2023–2030 (USD MILLION) 172
TABLE 129 ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY DELIVERY MODE, 2023–2030 (USD MILLION) 172
TABLE 130 ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 173
TABLE 131 ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE,
2023–2030 (USD MILLION) 173
TABLE 132 ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY MODEL,
2023–2030 (USD MILLION) 173
TABLE 133 ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY INTERACTIVITY LEVEL, 2023–2030 (USD MILLION) 174
TABLE 134 ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 174
TABLE 135 ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY SETTING, 2023–2030 (USD MILLION) 174
TABLE 136 JAPAN: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT,
2023–2030 (USD MILLION) 175
TABLE 137 JAPAN: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DELIVERY MODE, 2023–2030 (USD MILLION) 175
TABLE 138 JAPAN: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 176
TABLE 139 JAPAN: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE,
2023–2030 (USD MILLION) 176
TABLE 140 JAPAN: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY MODEL,
2023–2030 (USD MILLION) 176
TABLE 141 JAPAN: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INTERACTIVITY LEVEL, 2023–2030 (USD MILLION) 177
TABLE 142 JAPAN: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 177
TABLE 143 JAPAN: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY SETTING,
2023–2030 (USD MILLION) 177
TABLE 144 CHINA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT,
2023–2030 (USD MILLION) 178
TABLE 145 CHINA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DELIVERY MODE, 2023–2030 (USD MILLION) 179
TABLE 146 CHINA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 179
TABLE 147 CHINA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE,
2023–2030 (USD MILLION) 179
TABLE 148 CHINA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY MODEL,
2023–2030 (USD MILLION) 180
TABLE 149 CHINA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INTERACTIVITY LEVEL, 2023–2030 (USD MILLION) 180
TABLE 150 CHINA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 180
TABLE 151 CHINA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY SETTING,
2023–2030 (USD MILLION) 181
TABLE 152 INDIA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT,
2023–2030 (USD MILLION) 181
TABLE 153 INDIA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DELIVERY MODE, 2023–2030 (USD MILLION) 182
TABLE 154 INDIA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 182
TABLE 155 INDIA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE,
2023–2030 (USD MILLION) 182
TABLE 156 INDIA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY MODEL,
2023–2030 (USD MILLION) 183
TABLE 157 INDIA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INTERACTIVITY LEVEL, 2023–2030 (USD MILLION) 183
TABLE 158 INDIA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 183
TABLE 159 INDIA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY SETTING,
2023–2030 (USD MILLION) 184
TABLE 160 REST OF ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY COMPONENT, 2023–2030 (USD MILLION) 185
TABLE 161 REST OF ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY DELIVERY MODE, 2023–2030 (USD MILLION) 185
TABLE 162 REST OF ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY PRODUCT, 2023–2030 (USD MILLION) 185
TABLE 163 REST OF ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 186
TABLE 164 REST OF ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY MODEL, 2023–2030 (USD MILLION) 186
TABLE 165 REST OF ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY INTERACTIVITY LEVEL, 2023–2030 (USD MILLION) 186
TABLE 166 REST OF ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 187
TABLE 167 REST OF ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY SETTING, 2023–2030 (USD MILLION) 187
TABLE 168 LATIN AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 188
TABLE 169 LATIN AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY COMPONENT, 2023–2030 (USD MILLION) 188
TABLE 170 LATIN AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY DELIVERY MODE, 2023–2030 (USD MILLION) 188
TABLE 171 LATIN AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 189
TABLE 172 LATIN AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE, 2023–2030 (USD MILLION) 189
TABLE 173 LATIN AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY MODEL, 2023–2030 (USD MILLION) 189
TABLE 174 LATIN AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY INTERACTIVITY LEVEL, 2023–2030 (USD MILLION) 190
TABLE 175 LATIN AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 190
TABLE 176 LATIN AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY SETTING, 2023–2030 (USD MILLION) 190
TABLE 177 BRAZIL: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT,
2023–2030 (USD MILLION) 191
TABLE 178 BRAZIL: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DELIVERY MODE, 2023–2030 (USD MILLION) 191
TABLE 179 BRAZIL: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 192
TABLE 180 BRAZIL: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE,
2023–2030 (USD MILLION) 192
TABLE 181 BRAZIL: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY MODEL,
2023–2030 (USD MILLION) 192
TABLE 182 BRAZIL: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY INTERACTIVITY LEVEL, 2023–2030 (USD MILLION) 193
TABLE 183 BRAZIL: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 193
TABLE 184 BRAZIL: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY SETTING,
2023–2030 (USD MILLION) 193
TABLE 185 MEXICO: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT, 2023–2030 (USD MILLION) 194
TABLE 186 MEXICO: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DELIVERY MODE, 2023–2030 (USD MILLION) 194
TABLE 187 MEXICO: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 195
TABLE 188 MEXICO: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE,
2023–2030 (USD MILLION) 195
TABLE 189 MEXICO: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY MODEL,
2023–2030 (USD MILLION) 195
TABLE 190 MEXICO: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY INTERACTIVITY LEVEL, 2023–2030 (USD MILLION) 196
TABLE 191 MEXICO: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 196
TABLE 192 MEXICO: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY SETTING,
2023–2030 (USD MILLION) 196
TABLE 193 REST OF LATIN AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY COMPONENT, 2023–2030 (USD MILLION) 197
TABLE 194 REST OF LATIN AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY DELIVERY MODE, 2023–2030 (USD MILLION) 197
TABLE 195 REST OF LATIN AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY PRODUCT, 2023–2030 (USD MILLION) 197
TABLE 196 REST OF LATIN AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 198
TABLE 197 REST OF LATIN AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY MODEL, 2023–2030 (USD MILLION) 198
TABLE 198 REST OF LATIN AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY INTERACTIVITY LEVEL, 2023–2030 (USD MILLION) 198
TABLE 199 REST OF LATIN AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 199
TABLE 200 REST OF LATIN AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY SETTING, 2023–2030 (USD MILLION) 199
TABLE 201 MIDDLE EAST & AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY REGION, 2023–2030 (USD MILLION) 200
TABLE 202 MIDDLE EAST & AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY COMPONENT, 2023–2030 (USD MILLION) 200
TABLE 203 MIDDLE EAST & AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY DELIVERY MODE, 2023–2030 (USD MILLION) 201
TABLE 204 MIDDLE EAST & AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY PRODUCT, 2023–2030 (USD MILLION) 201
TABLE 205 MIDDLE EAST & AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 201
TABLE 206 MIDDLE EAST & AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY MODEL, 2023–2030 (USD MILLION) 202
TABLE 207 MIDDLE EAST & AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY INTERACTIVITY LEVEL, 2023–2030 (USD MILLION) 202
TABLE 208 MIDDLE EAST & AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 202
TABLE 209 MIDDLE EAST & AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY SETTING, 2023–2030 (USD MILLION) 203
TABLE 210 GCC COUNTRIES: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY COMPONENT, 2023–2030 (USD MILLION) 203
TABLE 211 GCC COUNTRIES: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY DELIVERY MODE, 2023–2030 (USD MILLION) 204
TABLE 212 GCC COUNTRIES: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 204
TABLE 213 GCC COUNTRIES: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE, 2023–2030 (USD MILLION) 204
TABLE 214 GCC COUNTRIES: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY MODEL, 2023–2030 (USD MILLION) 205
TABLE 215 GCC COUNTRIES: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY INTERACTIVITY LEVEL, 2023–2030 (USD MILLION) 205
TABLE 216 GCC COUNTRIES: CLINICAL DECISION SUPPORT SYSTEMS MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 205
TABLE 217 GCC COUNTRIES: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY SETTING, 2023–2030 (USD MILLION) 206
TABLE 218 REST OF MIDDLE EAST & AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT, 2023–2030 (USD MILLION) 206
TABLE 219 REST OF MIDDLE EAST & AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DELIVERY MODE, 2023–2030 (USD MILLION) 206
TABLE 220 REST OF MIDDLE EAST & AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 207
TABLE 221 REST OF MIDDLE EAST & AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE, 2023–2030 (USD MILLION) 207
TABLE 222 REST OF MIDDLE EAST & AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY MODEL, 2023–2030 (USD MILLION) 207
TABLE 223 REST OF MIDDLE EAST & AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INTERACTIVITY LEVEL, 2023–2030 (USD MILLION) 208
TABLE 224 REST OF MIDDLE EAST & AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 208
TABLE 225 REST OF MIDDLE EAST & AFRICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY SETTING, 2023–2030 (USD MILLION) 208
TABLE 226 CLINICAL DECISION SUPPORT SYSTEMS MARKET: OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS, 2022–2025 209
TABLE 227 CLINICAL DECISION SUPPORT SYSTEMS MARKET: REGION FOOTPRINT 218
TABLE 228 CLINICAL DECISION SUPPORT SYSTEMS MARKET: APPLICATION &
PRODUCT FOOTPRINT 219
TABLE 229 CLINICAL DECISION SUPPORT SYSTEMS MARKET: TYPE FOOTPRINT 219
TABLE 230 CLINICAL DECISION SUPPORT SYSTEMS MARKET: DETAILED LIST
OF KEY STARTUPS/SMES 222
TABLE 231 CLINICAL DECISION SUPPORT SYSTEMS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES 223
TABLE 232 CLINICAL DECISION SUPPORT SYSTEMS MARKET: SOLUTION LAUNCHES/ENHANCEMENTS/APPROVALS, JANUARY 2022–MAY 2025 224
TABLE 233 CLINICAL DECISION SUPPORT SYSTEMS MARKET: DEALS,
JANUARY 2022–MAY 2025 225
TABLE 234 CLINICAL DECISION SUPPORT SYSTEMS MARKET: OTHER DEVELOPMENTS, JANUARY 2022–MAY 2025) 227
TABLE 235 EPIC SYSTEMS CORPORATION: COMPANY OVERVIEW 228
TABLE 236 EPIC SYSTEMS CORPORATION: SOLUTIONS OFFERED 228
TABLE 237 EPIC SYSTEMS CORPORATION: SOLUTION LAUNCHES/ENHANCEMENTS/APPROVALS, JANUARY 2022–MAY 2025 229
TABLE 238 EPIC SYSTEMS CORPORATION: DEALS, JANUARY 2022–MAY 2025 229
TABLE 239 EPIC SYSTEMS CORPORATION: OTHER DEVELOPMENTS,
JANUARY 2022–MAY 2025 230
TABLE 240 WOLTERS KLUWER N.V.: COMPANY OVERVIEW 232
TABLE 241 WOLTERS KLUWER N.V.: SOLUTIONS OFFERED 233
TABLE 242 WOLTERS KLUWER N.V.: SOLUTION LAUNCHES/ENHANCEMENTS/APPROVALS, JANUARY 2022–MAY 2025 234
TABLE 243 WOLTERS KLUWER N.V.: DEALS, JANUARY 2022–MAY 2025 235
TABLE 244 WOLTERS KLUWER N.V.: OTHER DEVELOPMENTS, JANUARY 2022–MAY 2025 237
TABLE 245 ORACLE: COMPANY OVERVIEW 238
TABLE 246 ORACLE: SOLUTIONS OFFERED 239
TABLE 247 ORACLE: SOLUTION LAUNCHES/ENHANCEMENTS/APPROVALS,
JANUARY 2022–MAY 2025 240
TABLE 248 ORACLE: DEALS, JANUARY 2022–MAY 2025 240
TABLE 249 MERATIVE: COMPANY OVERVIEW 243
TABLE 250 MERATIVE: SOLUTIONS OFFERED 243
TABLE 251 MERATIVE: SOLUTION LAUNCHES/ENHANCEMENTS/APPROVALS,
JANUARY 2022–MAY 2025 244
TABLE 252 MERATIVE: DEALS, JANUARY 2022–MAY 2025 244
TABLE 253 MERATIVE: OTHER DEVELOPMENTS, JANUARY 2022–MAY 2025 244
TABLE 254 VERADIGM LLC: COMPANY OVERVIEW 246
TABLE 255 VERADIGM LLC: SOLUTIONS OFFERED 247
TABLE 256 VERADIGM LLC: SOLUTION LAUNCHES/ENHANCEMENTS/APPROVALS,
JANUARY 2022–MAY 2025 248
TABLE 257 VERADIGM LLC: DEALS, JANUARY 2022–MAY 2025 249
TABLE 258 VERADIGM LLC: OTHER DEVELOPMENTS, JANUARY 2022–MAY 2025 250
TABLE 259 OPTUM, INC.: COMPANY OVERVIEW 252
TABLE 260 OPTUM, INC.: SOLUTIONS OFFERED 253
TABLE 261 OPTUM, INC.: SOLUTION LAUNCHES/ENHANCEMENTS/APPROVALS,
JANUARY 2022–MAY 2025 253
TABLE 262 OPTUM, INC.: DEALS, JANUARY 2022–MAY 2025 253
TABLE 263 ATHENAHEALTH: COMPANY OVERVIEW 254
TABLE 264 ATHENAHEALTH: SOLUTIONS OFFERED 254
TABLE 265 ATHENAHEALTH: SOLUTION LAUNCHES/ENHANCEMENTS/APPROVALS,
JANUARY 2022–MAY 2025 255
TABLE 266 ATHENAHEALTH: DEALS, JANUARY 2022–MAY 2025 255
TABLE 267 ELSEVIER: COMPANY OVERVIEW 257
TABLE 268 ELSEVIER: SOLUTIONS OFFERED 257
TABLE 269 ELSEVIER: SOLUTION LAUNCHES/ENHANCEMENTS/APPROVALS,
JANUARY 2022–MAY 2025 258
TABLE 270 ELSEVIER: DEALS, JANUARY 2022–MAY 2025 259
TABLE 271 ZYNX HEALTH, INC.: COMPANY OVERVIEW 260
TABLE 272 ZYNX HEALTH, INC.: SOLUTIONS OFFERED 260
TABLE 273 ZYNX HEALTH, INC.: SOLUTION LAUNCHES/ENHANCEMENTS/APPROVALS, JANUARY 2022–MAY 2025 261
TABLE 274 ZYNX HEALTH, INC.: DEALS, JANUARY 2022–MAY 2025 262
TABLE 275 ZYNX HEALTH, INC.: OTHER DEVELOPMENTS, JANUARY 2022–MAY 2025 262
TABLE 276 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW 263
TABLE 277 KONINKLIJKE PHILIPS N.V.: SOLUTIONS OFFERED 264
TABLE 278 KONINKLIJKE PHILIPS N.V.: PRODUCT LAUNCHES/ENHANCEMENTS/APPROVALS, JANUARY 2022–MAY 2025 265
TABLE 279 MEDICAL INFORMATION TECHNOLOGY, INC.: COMPANY OVERVIEW 266
TABLE 280 MEDICAL INFORMATION TECHNOLOGY, INC.: SOLUTIONS OFFERED 266
TABLE 281 MEDICAL INFORMATION TECHNOLOGY, INC.: PRODUCT LAUNCHES/ENHANCEMENTS/APPROVALS, JANUARY 2022–MAY 2025 267
TABLE 282 MEDICAL INFORMATION TECHNOLOGY, INC.: DEALS, JANUARY 2022–MAY 2025 267
TABLE 283 MEDICAL INFORMATION TECHNOLOGY, INC.: OTHER DEVELOPMENTS,
JANUARY 2022–MAY 2025 269
TABLE 284 NEXTGEN HEALTHCARE, INC.: COMPANY OVERVIEW 270
TABLE 285 NEXTGEN HEALTHCARE, INC.: SOLUTIONS OFFERED 271
TABLE 286 NEXTGEN HEALTHCARE, INC.: SOLUTION LAUNCHES/ENHANCEMENTS/APPROVALS, JANUARY 2022–MAY 2025 272
TABLE 287 NEXTGEN HEALTHCARE, INC.: DEALS, JANUARY 2022–MAY 2025 272
TABLE 288 NEXTGEN HEALTHCARE, INC.: OTHER DEVELOPMENTS, JANUARY 2022–MAY 2025 273
TABLE 289 CUREMD HEALTHCARE: COMPANY OVERVIEW 274
TABLE 290 CUREMD HEALTHCARE: SOLUTIONS OFFERED 274
TABLE 291 CUREMD HEALTHCARE: DEALS, JANUARY 2022–MAY 2025 276
TABLE 292 CUREMD HEALTHCARE: OTHER DEVELOPMENTS, JANUARY 2022–MAY 2025 276
TABLE 293 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 277
TABLE 294 SIEMENS HEALTHINEERS AG: SOLUTIONS OFFERED 278
TABLE 295 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2022–MAY 2025 279
TABLE 296 EBSCO INFORMATION SERVICES: COMPANY OVERVIEW 280
TABLE 297 EBSCO INFORMATION SERVICES: SOLUTIONS OFFERED 280
TABLE 298 EBSCO INFORMATION SERVICES: SOLUTION LAUNCHES/ENHANCEMENTS/UPGRADES, JANUARY 2022–MAY 2025 282
TABLE 299 EBSCO INFORMATION SERVICES: DEALS, JANUARY 2022–MAY 2025 282
TABLE 300 EBSCO INFORMATION SERVICES: OTHER DEVELOPMENTS,
JANUARY 2022–MAY 2025 283
TABLE 301 GE HEALTHCARE: COMPANY OVERVIEW 284
TABLE 302 GE HEALTHCARE: SOLUTIONS OFFERED 285
TABLE 303 GE HEALTHCARE: SOLUTION LAUNCHES/ENHANCEMENTS/APPROVALS,
JANUARY 2022–MAY 2025 286
TABLE 304 GE HEALTHCARE: DEALS, JANUARY 2022–MAY 2025 286
TABLE 305 GE HEALTHCARE: OTHER DEVELOPMENTS, JANUARY 2022–MAY 2025 287
TABLE 306 ECLINICALWORKS: COMPANY OVERVIEW 288
TABLE 307 ECLINICALWORKS: SOLUTIONS OFFERED 288
TABLE 308 ECLINICALWORKS: SOLUTION LAUNCHES/ENHANCEMENTS/APPROVALS,
JANUARY 2022–MAY 2025 289
TABLE 309 ECLINICALWORKS: DEALS, JANUARY 2022–MAY 2025 289
TABLE 310 THE MEDICAL ALGORITHMS COMPANY LIMITED: COMPANY OVERVIEW 291
TABLE 311 THE MEDICAL ALGORITHMS COMPANY LIMITED: SOLUTIONS OFFERED 291
TABLE 312 CARECLOUD, INC.: COMPANY OVERVIEW 292
TABLE 313 CARECLOUD, INC.: SOLUTIONS OFFERED 293
TABLE 314 CARECLOUD, INC.: SOLUTION LAUNCHES/ENHANCEMENTS/APPROVALS,
JANUARY 2022–MAY 2025 294
TABLE 315 CARECLOUD, INC.: DEALS, JANUARY 2022–MAY 2025 294
TABLE 316 CARECLOUD, INC.: EXPANSIONS, JANUARY 2022–MAY 2025 295
TABLE 317 RAMPMEDICAL: COMPANY OVERVIEW 296
TABLE 318 RAMPMEDICAL: SOLUTIONS OFFERED 296
TABLE 319 MACUSOFT: COMPANY OVERVIEW 297
TABLE 320 HERA-MI: COMPANY OVERVIEW 298
TABLE 321 COHESIC INC.: COMPANY OVERVIEW 298
TABLE 322 MEDEA MIND: COMPANY OVERVIEW 299
TABLE 323 GLASS HEALTH: COMPANY OVERVIEW 299
TABLE 324 MEDECIPHER: COMPANY OVERVIEW 300
LIST OF FIGURES
FIGURE 1 CLINICAL DECISION SUPPORT SYSTEMS MARKET SEGMENTATION AND
REGIONS COVERED 31
FIGURE 2 RESEARCH DESIGN 35
FIGURE 3 PRIMARY SOURCES 38
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,
AND REGION 40
FIGURE 5 HYPOTHESIS BUILDING 41
FIGURE 6 RESEARCH METHODOLOGY: MARKET SIZE ESTIMATION 42
FIGURE 7 APPROACH 2: DEMAND-SIDE ANALYSIS 43
FIGURE 8 APPROACH 3: BOTTOM-UP AND SEGMENTAL EXTRAPOLATION 44
FIGURE 9 CAGR PROJECTIONS FROM ANALYSIS OF MARKET DYNAMICS 45
FIGURE 10 CLINICAL DECISION SUPPORT SYSTEMS MARKET: CAGR PROJECTION ANALYSIS 45
FIGURE 11 DATA TRIANGULATION METHODOLOGY 47
FIGURE 12 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY COMPONENT,
2025 VS. 2030 (USD MILLION) 50
FIGURE 13 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY PRODUCT,
2025 VS. 2030 (USD MILLION) 51
FIGURE 14 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY TYPE,
2025 VS. 2030 (USD MILLION) 51
FIGURE 15 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY MODEL,
2025 VS. 2030 (USD MILLION) 52
FIGURE 16 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY APPLICATION,
2025 VS. 2030 (USD MILLION) 53
FIGURE 17 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY DELIVERY MODE,
2025 VS. 2030 (USD MILLION) 53
FIGURE 18 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY INTERACTIVITY LEVEL,
2025 VS. 2030 (USD MILLION) 54
FIGURE 19 CLINICAL DECISION SUPPORT SYSTEMS MARKET, BY SETTING,
2025 VS. 2030 (USD MILLION) 55
FIGURE 20 GEOGRAPHICAL SNAPSHOT OF CLINICAL DECISION SUPPORT SYSTEMS MARKET 56
FIGURE 21 GROWING IMPLEMENTATION OF HCIT SOLUTIONS TO DRIVE MARKET 57
FIGURE 22 INTEGRATED CDSS SEGMENT AND US LED NORTH AMERICAN MARKET IN 2024 58
FIGURE 23 CHINA TO ACCOUNT FOR HIGHEST GROWTH DURING FORECAST PERIOD 58
FIGURE 24 ASIA PACIFIC MARKET TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD 59
FIGURE 25 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH RATE
DURING FORECAST PERIOD 59
FIGURE 26 CLINICAL DECISION SUPPORT SYSTEMS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 60
FIGURE 27 REVENUE SHIFTS AND NEW REVENUE POCKETS FOR CLINICAL
DECISION SUPPORT SYSTEMS MARKET 70
FIGURE 28 AVERAGE SELLING PRICE OF KEY PLAYERS, BY PRODUCT, 2024 (USD) 71
FIGURE 29 CLINICAL DECISION SUPPORT SYSTEMS MARKET: VALUE CHAIN ANALYSIS 72
FIGURE 30 CLINICAL DECISION SUPPORT SYSTEM MARKET: ECOSYSTEM ANALYSIS 73
FIGURE 31 JURISDICTION ANALYSIS OF PATENTS, 2015–2025 76
FIGURE 32 CLINICAL DECISION SUPPORT SYSTEMS MARKET: PATENT ANALYSIS,
JANUARY 2015–MAY 2025 77
FIGURE 33 CLINICAL DECISION SUPPORT SYSTEMS MARKET: PORTER’S
FIVE FORCES ANALYSIS 91
FIGURE 34 BENEFITS OF HYBRID BUSINESS MODELS 94
FIGURE 35 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS 95
FIGURE 36 KEY BUYING CRITERIA FOR TOP THREE COMPONENTS 96
FIGURE 37 NORTH AMERICA: CLINICAL DECISION SUPPORT SYSTEMS MARKET SNAPSHOT 138
FIGURE 38 ASIA PACIFIC: CLINICAL DECISION SUPPORT SYSTEMS MARKET SNAPSHOT 171
FIGURE 39 REVENUE SHARE ANALYSIS, 2020–2024 211
FIGURE 40 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024 212
FIGURE 41 EV/EBITDA OF KEY VENDORS 213
FIGURE 42 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF VENDORS 214
FIGURE 43 CLINICAL DECISION SUPPORT SYSTEMS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 215
FIGURE 44 CLINICAL DECISION SUPPORT SYSTEMS MARKET: COMPANY EVALUATION
MATRIX, 2024 217
FIGURE 45 CLINICAL DECISION SUPPORT SYSTEMS MARKET: COMPANY FOOTPRINT 218
FIGURE 46 CLINICAL DECISION SUPPORT SYSTEMS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 221
FIGURE 47 WOLTERS KLUWER N.V.: COMPANY SNAPSHOT (2024) 233
FIGURE 48 ORACLE: COMPANY SNAPSHOT (2023) 239
FIGURE 49 VERADIGM LLC: COMPANY SNAPSHOT (2022) 247
FIGURE 50 UNITEDHEALTH GROUP: COMPANY SNAPSHOT (2024) 252
FIGURE 51 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2024) 264
FIGURE 52 NEXTGEN HEALTHCARE, INC.: COMPANY SNAPSHOT (2023) 270
FIGURE 53 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2024) 278
FIGURE 54 GE HEALTHCARE: COMPANY SNAPSHOT (2024) 285
FIGURE 55 CARECLOUD, INC.: COMPANY SNAPSHOT (2024) 292
MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
- 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
- ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11